Human Papillomavirus Infections Pipeline Analysis - KSWO, Lawton, OK- Wichita Falls, TX: News, Weather, Sports. ABC, 24/7, Telemundo -

Human Papillomavirus Infections Pipeline Analysis

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Research and Markets

DUBLIN, June 26, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/2q42ms/human) has announced the addition of the "Human Papillomavirus Infections Pipeline Analysis" report to their offering.

http://photos.prnewswire.com/prnh/20130307/600769

Currently there is significant amount of research being undertaken to study the process of HPV infection causing precancerous changes in normal cells. Also, methods to prevent and manage this situation are also being analyzed. A majority of these studies were previously focusing on cervical cells in women.

But in recent years, the realm of research has been extended to other tissues also in which HPV may cause cancer, such as the oropharynx and anus. Also, many organizations are analyzing the use of second-generation preventive vaccines along with therapeutic HPV vaccines, which could possibly prevent the development of cancer among women previously infected with HPV. Such an ideal vaccine strategy would combine a preventive and therapeutic vaccine, which would help in a major way.

The mechanism of the HPV vaccines is similar to the other immunizations which help in protecting against viral infections. It has been observed and analyzed that the unique surface components of HPV have the capability to create an antibody response which could possibly protect the human body against infection.

These components could thus be used as a basis of the vaccine. There are only 2 HPV vaccines which are currently marketed across the globe. Both these vaccines are prepared using the recombinant technology, which is taken from purified L1 structural proteins which self assemble to form HPV type-specific empty shells or virus-like particles (VLPs).

Since there are no therapeutic HPV vaccines available at present which have proved their efficiency in the clinical trials, there is still a lot of work which is required in this field, thus opening a large window of opportunities. There have been some technological advancements in the past 4-5 years. The future is also likely to continue to witness similar technological and medical success in terms of new drugs and efficient vaccines, with the help of adequate funding.

Certain developments like a new treatment to reduce transmissibility in drug users and new efforts to strengthen the immune system have the potential to develop further and provide better healthcare services to the patients in the future. Thus, there needs to be more focus being given to increasing the knowledge and awareness about HPV infections and the ways and methods to treat it, either through drugs or through vaccines.

Key Topics Covered:

1. Global Human Papillomavirus Infection Drug Market Overview

2. Human Papillomavirus Infections Drug Clinical Trial Insight by Phase & Country

3. Marketed Human Papillomavirus Drug Profile

4. No Development Reported & Discontinued HPV Drug Profiles

5. Competitive Landscape

Companies Mentioned:

  • Advanced Viral Research
  • BioSphings,
  • Biogen Idec,
  • EyeGene,
  • Helix BioPharma,
  • Inviragen,
  • MedImmune,
  • Merck & Co,
  • Valeant Pharmaceuticals

For more information visit http://www.researchandmarkets.com/research/2q42ms/human

Media Contact: Laura Wood, +353-1-481-1716, press@researchandmarkets.net

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow
KSWO-TV, 1401 SE 60th Street
Lawton, OK 73501

Telephone: (580) 355-7000
Fax: (580) 357-3811
Email: news@kswo.com

All content © Copyright 2000 - 2014 Worldnow and KSWO. All Rights Reserved. For more information on this site, please read our Privacy Policy and Terms of Service.